Glaxo's Viiv Healthcare granted FDA approval for HIV tablet

ViiV Healthcare, the specialist HIV company set up by GlaxoSmithKline and Pfizer, has received approval from the Food and Drug Administration (FDA) for Triumeq, its tablet form treatment of the HIV-1 infection.The treatment offers people a single-pill regimen containing dolutegravir, which was itself approved for use in the US in 2013 and Europe at the start of this year. Approval was granted primarily based on data from two clinical trials which compared dolutegravir taken as a separate pill with a pill that combines it into a single pill that also contains abacavir and lamivudine. Dr Dominique Limet, chief executive officer of ViiV Healthcare, said: "Today's approval of Triumeq offers many people living with HIV in the US the first single-pill regimen containing dolutegravir. ViiV Healthcare is committed to delivering advances in care and new treatment options to physicians and people living with HIV. "We are proud to announce this important milestone, marking the second new treatment to be approved in the US from our pipeline of medicines."Shares had risen 0.86% to 1,441.85p by 08:47.NR